Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00225173 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease
A Phase 2 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00225173: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT00225173 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00225173, a Phase 2 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
Patients with 3 or more adverse prognostic factors have a higher relapse rate. Significant anti-tumor activity in Hodgkin's lymphoma has been reported with two new drugs:gemcitabine and vinorelbine. The introduction of these new agents with their different mechanisms of action into the Stanford V regimen may increase effectiveness while maintaining a favorable toxicity profile with respect to fertility and a low risk of secondary leukemia. On this basis, we propose a new regimen, Stanford VI, for patients with bulky and advanced HD with 3 or more risk factors.
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Etoposide
- DRUG Vincristine
- DRUG Vinblastine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2001-10 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00225173
The ClinicalTrials.gov registry entry for NCT00225173 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00225173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00225173 about?
NCT00225173 is a clinical study titled "Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease". Patients with 3 or more adverse prognostic factors have a higher relapse rate. Significant anti-tumor activity in Hodgkin's lymphoma has been reported with two new drugs:gemcitabine and vinorelbine. The introduction of these new agents with their different mechanisms of action into the Stanford V re...
What is the current status of trial NCT00225173?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2001-10. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00225173?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Etoposide (DRUG), Vincristine (DRUG), Vinblastine (DRUG).
Who is sponsoring clinical trial NCT00225173?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.